Shanghai has stepped up its efforts to protect intellectual property rights (IPR) in the field of biomedicine, one of the three industries that the central government has entrusted the city to build into world-class industrial clusters.

The Shanghai Intellectual Property Administration has handled a number of influential administrative adjudication cases that pertain to patent infringement in biomedicine, effectively de-escalating disputes and safeguarding the legitimate rights and interests of biomedical enterprises.

Multinational pharmaceutical companies such as Bayer, Boehringer Ingelheim, Roche, and Takeda have expressed their appreciation and confidence in Shanghai's sound IPR protection system, which they believe encourages innovation and investment.

The city has also explored a linkage protection mechanism in the drug procurement link, and has established a consultation and coordination mechanism with the city's medical insurance department to promptly remove infringing drugs from medical insurance platforms.

In addition, the city has improved the effectiveness of IPR protection by strengthening source protection, and providing one-stop services for biomedicine and other industries in Pudong New Area. It has also enhanced technical support for administrative adjudication of patent infringement disputes in biomedicine and other fields.